Ziftomenib( —— )

Catalog No. M35131 CAS No. 2134675-36-6

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

Ziftomenib
Note

Research use only, not for human use.
Brief Description

Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.
Description

Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).
In Vitro

The mixed-lineage leukemia (MLL) protein is a histone methyltransferase critical for the epigenetic regulation of gene transcription. Many acute leukemias, including acute myeloblastic leukemia (AML), acute lymphoblastic leukemia (ALL) and mixed-lineage leukemia (MLL), are characterized by the presence of chimeric MLL fusion proteins that result from chromosomal translocations of the MLL gene located at chromosome 11, band q23 (11q23). MLL fusion proteins lack the original histone methyltransferase activity of the C-terminus of MLL and gain the ability to regulate transcription of numerous oncogenes, including HOX and MEIS1, resulting in increased cell proliferation and decreased cell differentiation, ultimately leading to leukemogenesis.
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Histone Methyltransferase
Research Area

——
Indication

——

CAS Number

2134675-36-6
Formula Weight

717.871
Molecular Formula

C33H42F3N9O2S2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (139.30 mM; Ultrasonic )
SMILES

CNc1nc(NC2CCN(Cc3ccc4n(C[C@H](C)N5CCN(CC5)S(C)(=O)=O)c(cc4c3C)C#N)CC2)c2cc(CC(F)(F)F)sc2n1
Chemical Name

——

1. Tao Wu, et al. Substituted inhibitors of menin-mll and methods of use. WO2017161028A1.

Calculator

molnova catalog